Sanjivani Paranteral Ltd
Sanjivani Paranteral Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores. FY '27 base business revenue targeted around INR 90 crores (up from INR 72-75 crores in FY '26).
From Sanjivani Paranteral Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores.
- SPL Infusion Private Limited (Pune JV) expected to contribute INR 60-65 crores in FY '27.
- Base business expected to grow around 18-20% in FY '27-'28, potentially higher.
- Post FY '27, growth driven by increased product approvals and market expansion, especially in West and East Africa.
- Pune infusion plant ramping up capacity from ~23% to 40-50% utilization in FY '27.
- Expansion in infusion product portfolio to 20-23 products by end of FY '27, exceeding competitors' 12-14.
- Export markets to continue being key revenue drivers, contributing ~77% of total revenue.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Sanjivani Paranteral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major capex cycle is currently over; all plants are operational.
- FY '27 capex planned at INR 4 to 4.5 crores, mainly for maintenance, machine upgrades, and software in injectable plants at Mumbai and Dehradun.
- No significant new capex expected in FY '27 beyond this recurring amount.
- Future growth is expected from ramp-up and approvals rather than large new investments.
- The Pune infusion JV plant is operational and ramping up capacity gradually; no major capex mentioned specifically for this.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanjivani Paranteral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders.
- However, it indicates strong growth driven primarily by export markets and product mix improvements.
- The Pune infusion facility and the Prague-based nutraceutical venture are ramping up, signaling expanding order flow.
- The company expects the infusion facility to have a product portfolio of around 20-23 products by November-December.
2 more points management made on order book & pipeline
Sanjivani Paranteral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹11 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanjiv.Parant.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Sanjivani Paranteral Ltd Q3 FY26 results?
FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores. FY '27 base business revenue targeted around INR 90 crores (up from INR 72-75 crores in FY '26).
What is Sanjivani Paranteral Ltd share price analysis?
Sanjivani Paranteral Ltd currently shows a neutral. The stock trades at a P/E of 35.2 with a market cap of ₹235 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sanjivani Paranteral Ltd planning capital expenditure?
Major capex cycle is currently over; all plants are operational.
Keep Sanjivani Paranteral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.